Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01595321 · ClinicalTrials.gov registry record · Phase 2
Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT01595321 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 19 participants.
The verdict
NCT01595321, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to estimate safety of GVAX Pancreas Vaccine (GVAX) with immune modulating doses of cyclophosphamide (Cy) followed by SBRT and FOLFIRINOX chemotherapy in pancreatic cancer patients after surgery.
Interventions
- DRUG Cyclophosphamide
- DRUG FOLFIRINOX
- BIOLOGICAL GVAX Pancreas Vaccine
- RADIATION Stereotactic Body Radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2012-10-29 |
| Est. Completion | 2023-10-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01595321
The ClinicalTrials.gov registry entry for NCT01595321 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT01595321 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01595321 about?
NCT01595321 is a clinical study titled "Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas". The purpose of this study is to estimate safety of GVAX Pancreas Vaccine (GVAX) with immune modulating doses of cyclophosphamide (Cy) followed by SBRT and FOLFIRINOX chemotherapy in pancreatic cancer patients after surgery.
What is the current status of trial NCT01595321?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2012-10-29. Estimated completion is 2023-10-18.
What interventions are being tested in trial NCT01595321?
The interventions under investigation include: Cyclophosphamide (DRUG), FOLFIRINOX (DRUG), GVAX Pancreas Vaccine (BIOLOGICAL), Stereotactic Body Radiation (RADIATION).
Who is sponsoring clinical trial NCT01595321?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.